All six patients received disease-modifying therapies (DMTs) for MS: four patients were treated with a single DMT (two on moderate-efficacy injectables like interferon-beta and two on high-efficacy therapies like fingolimod), and the remaining two patients required escalation through multiple DMTs (they started with intravenous immunoglobulin during early childhood, when DMTs were contraindicated due to their age, and then switched to interferon and later to fingolimod, which are the therapies available in our country for pediatric MS). This evidence concerns the gene IFNB1 and myeloid sarcoma.